Literature DB >> 15142116

FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact.

Wing Y Au1, Alvin Fung, Chor S Chim, Albert K Lie, Raymond Liang, Edmond S K Ma, Cheuk H Chan, Kit F Wong, Yok L Kwong.   

Abstract

FLT-3 aberrations that occur as an internal tandem duplication (ITD) or a mutation at the activation-loop position 835, D835, are common in acute promyelocytic leukaemia (APL). We investigated the clinicopathological associations and prognostic impact of FLT-3 aberrations in a cohort of APL patients. FLT-3 exons 11 and 12 were amplified by polymerase chain reaction (PCR), and the ITD was recognized as an increase in the size of the PCR product. FLT-3 exon 17 was amplified, and D835 mutation was identified by loss of an EcoRV site, followed by DNA sequencing. Of 82 patients studied, FLT-3 aberrations were detected in 35 cases (43%) at diagnosis (ITD: 16; D835 mutation: 18; ITD + D835 mutation: 1). FLT-3 ITD, but not D835 mutations, was significantly associated with higher presentation white blood cell count (WBC) and microgranular morphology. Early/induction deaths were related to male sex and high presentation WBC. There was a trend for FLT-3 ITD to be associated with non-remission (P = 0.06). For disease-free survival, high WBC was the only significant adverse factor. Male sex, high WBC and FLT-3 ITD were significant adverse factors for overall survival. These findings have important implications on the possible use of FLT-3 inhibitors in the treatment of APL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142116     DOI: 10.1111/j.1365-2141.2004.04935.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Authors:  Harry Iland; Ken Bradstock; John Seymour; Mark Hertzberg; Andrew Grigg; Kerry Taylor; John Catalano; Paul Cannell; Noemi Horvath; Sandra Deveridge; Peter Browett; Tim Brighton; Li Chong; Francisca Springall; Juliet Ayling; Alberto Catalano; Shane Supple; Marnie Collins; Juliana Di Iulio; John Reynolds
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Authors:  Muhamed Baljevic; Bogdan Dumitriu; Ju-Whei Lee; Elisabeth M Paietta; Peter H Wiernik; Janis Racevskis; Christina Chen; Eytan M Stein; Robert E Gallagher; Jacob M Rowe; Frederick R Appelbaum; Bayard L Powell; Richard A Larson; Steven E Coutré; Jeffrey Lancet; Mark R Litzow; Selina M Luger; Neal S Young; Martin S Tallman
Journal:  Acta Haematol       Date:  2016-09-16       Impact factor: 2.195

3.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.

Authors:  Matthew A Kutny; Barry K Moser; Kristina Laumann; James H Feusner; Alan Gamis; John Gregory; Richard A Larson; Bayard L Powell; Wendy Stock; Cheryl L Willman; William G Woods; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

5.  Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre.

Authors:  Farheen Karim; Usman Shaikh; Salman Naseem Adil; Mohammad Khurshid
Journal:  Singapore Med J       Date:  2014-08       Impact factor: 1.858

6.  Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.

Authors:  Harshabad Singh; Lillian Werner; Daniel Deangelo; Karen Ballen; Philip Amrein; Martha Wadleigh; Donna Neuberg; Edward Fox; Richard Stone; Eyal Attar
Journal:  Am J Hematol       Date:  2010-12       Impact factor: 10.047

7.  Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Authors:  Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

8.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Authors:  Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles A Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

9.  Mobilization of CD34+ progenitor cells in association with decreased proliferation in the bone marrow of macaques after administration of the Fms-like tyrosine kinase 3 ligand.

Authors:  R Keith Reeves; Qing Wei; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

10.  Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

Authors:  Xavier Poiré; Barry K Moser; Robert E Gallagher; Kristina Laumann; Clara D Bloomfield; Bayard L Powell; Gregory Koval; Kabir Gulati; Nicholas Holowka; Richard A Larson; Martin S Tallman; Frederick R Appelbaum; Dorie Sher; Cheryl Willman; Elisabeth Paietta; Wendy Stock
Journal:  Leuk Lymphoma       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.